ARTIVA BIOTHERAPEUTICS INC Form 4 Filings

Artiva Biotherapeutics, Inc. (ARTV) reported that director Laura Stoppel received a grant of 13,750 stock options on September 8, 2026. These options have an exercise price of $10.88 per share and become fully vested on the earlier of September 8, 2027, or the company’s 2027 annual stockholder meeting. The options expire on September 7, 2036, and no Rule 10b5-1 trading plan is reported for this grant.

Artiva Biotherapeutics, Inc. (ARTV) reported that director Elaine K. Sorg received a grant of 13,750 director stock options on September 8, 2026. The options have an exercise price of $10.88 per share and expire on September 7, 2036. According to the award terms, all shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of Artiva Biotherapeutics, Inc.'s 2027 annual stockholder meeting. Following this grant, Sorg holds 13,750 options directly.

Artiva Biotherapeutics, Inc. (ARTV) reported that director Elizabeth L. Hougen received a grant of 13,750 Director Stock Options on September 8, 2026. The options have an exercise price of $10.88 per share and will vest in full on the earlier of September 8, 2027 or the company’s 2027 annual stockholder meeting. Following this grant, she holds 13,750 options directly, expiring on September 7, 2036; no Rule 10b5-1 trading plan is reported.

Artiva Biotherapeutics, Inc. (ARTV) reported that director Brian Daniels received a grant of options to purchase 13,750 shares of Common Stock on September 8, 2026. The options have an exercise price of $10.88 per share and expire on September 7, 2036.

These options will vest in full on the earlier of September 8, 2027, or the date of Artiva’s 2027 annual stockholder meeting, and Daniels now holds 13,750 option shares directly after this grant. No Rule 10b5-1 trading plan is reported for this award.

Artiva Biotherapeutics, Inc. (ARTV) reported that director Daniel G. Baker received a stock option award for 13,750 shares of common stock on September 8, 2026. The option has an exercise price of $10.88 per share and expires on September 7, 2036.

The option vests in full on the earlier of September 8, 2027 or the date of Artiva Biotherapeutics’ 2027 annual stockholder meeting, and following this grant Baker holds 13,750 option shares directly.

Artiva Biotherapeutics, Inc. (ARTV) reported that director Alison Moore received a grant of 13,750 stock options on September 8, 2026. The options have an exercise price of $10.88 per share, expire on September 7, 2036, and vest in full on the earlier of September 8, 2027, or the company’s 2027 annual stockholder meeting. No Rule 10b5-1 trading plan is reported for this grant.

Artiva Biotherapeutics, Inc. (ARTV) reported that Chief Tech Operations Officer Christopher Horan sold 10,366 shares of common stock on September 3, 2026, at a weighted average price of $11.1555 per share. According to the company’s sell-to-cover policy, these automatic sales were made solely to satisfy tax withholding obligations from vesting restricted stock units, and Horan held 283,084 shares directly after the transaction.

Artiva Biotherapeutics, Inc. (ARTV) reported that officer Jennifer Bush, the company's COO, CLO and Compliance Officer, sold 8,391 shares of common stock on September 3, 2026. The company states these sales were automatic sell-to-cover transactions for tax withholding on vesting restricted stock units, not discretionary trades, leaving her with 329,529 shares held directly.

Artiva Biotherapeutics, Inc. (ARTV) reported that Chief Medical Officer Subhashis Banerjee sold 1,100 shares of common stock on September 3, 2026 at $11.1556 per share. According to the company’s sell-to-cover policy, this automatic sale was made solely to cover tax withholding from vested restricted stock units, and Banerjee now holds 140,947 shares directly.

Artiva Biotherapeutics, Inc. (ARTV) reported that Chief Executive Officer Fred Aslan sold 61,888 shares of common stock on September 3, 2026 at a weighted average price of $11.1555 per share. The company states these automatic sales were made solely to cover tax withholding on vested restricted stock units, under a corporate sell-to-cover policy. Following the transaction, Aslan directly held 1,473,194 shares of Artiva common stock.

Artiva Biotherapeutics, Inc. (ARTV) reported insider transactions by Chief Medical Officer Subhashis Banerjee on August 27, 2026. Banerjee exercised 5,306 stock options at $1.92 per share to acquire the same number of common shares, then sold 8,222 common shares at a weighted average of $12.0087 per share. The option exercise left 74,265 options outstanding and was carried out under a Rule 10b5-1 trading plan adopted on May 14, 2026.

Artiva Biotherapeutics, Inc. (ARTV) reported that Chief Medical Officer Subhashis Banerjee exercised employee stock options for 429 shares of common stock at an exercise price of $1.92 per share and immediately sold 429 shares of common stock at $12.00 per share on 2026-08-18. Following the option exercise, Banerjee held 79,571 stock options. The transactions occurred pursuant to a Rule 10b5-1 Plan adopted on May 14, 2026. The option grant vested 25% on April 8, 2026, with the remaining shares vesting monthly over the following 36 months.

RA Capital Management-affiliated investment vehicles reported open-market purchases of 45,768 shares of Artiva Biotherapeutics common stock. On July 29, 2026 they bought 20,824 shares at a weighted average price of $9.99, and on July 31 they bought 24,944 shares at $9.93.

The shares are held indirectly through RA Capital-managed funds and a separately managed account, and the adviser and related parties disclaim beneficial ownership beyond their pecuniary interests. A partner of the adviser serves on Artiva’s board, providing board representation for these investors.

RA Capital Management, L.P. and affiliated funds reported purchasing 41,319 shares of Artiva Biotherapeutics, Inc. common stock on July 24, 2026 at a weighted average price of $9.99 per share, with trades between $9.96 and $10.00, held indirectly by RA Capital Healthcare Fund LP. The Adviser, its general partner, and Dr. Peter Kolchinsky and Mr. Rajeev Shah act as investment manager and managing members and disclaim beneficial ownership except to the extent of their pecuniary interest; additional Artiva shares are held through RA Capital Nexus funds and a separately managed account under similar terms.

RA Capital Healthcare Fund LP, advised by RA Capital Management, reported open-market purchases of 264,586 shares of Artiva Biotherapeutics common stock on July 21–23, 2026, at weighted average prices of $9.55, $9.93, and $9.96 per share. The RA Capital entities and principals disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.

Entities affiliated with RA Capital Management, L.P., significant stockholders and directors of Artiva Biotherapeutics, Inc., purchased 6,522 shares of common stock on July 13, 2026 at a weighted-average price of $8.94 per share (range $8.89–$8.95). Following this indirect purchase, the RA Capital funds reported holding 16,817,543 shares of Artiva common stock. The amendment corrects an earlier Form 4 share count, and notes the shares are held by RA Capital Healthcare Fund, L.P., with the Adviser and related parties disclaiming beneficial ownership except to the extent of their pecuniary interests.

Artiva Biotherapeutics, Inc. reported indirect insider purchases by RA Capital–managed entities. On July 16, 2026, they purchased 152,472 common shares in open-market or private transactions at a weighted average price of $8.93 per share, with individual prices from $8.79 to $9.00. On July 17, 2026, they purchased 7,882 shares at a weighted average price of $8.95, with trades between $8.88 and $9.00.

The shares are held directly by RA Capital Healthcare Fund, RA Capital Nexus Fund, RA Capital Nexus Fund III and a separately managed account for which RA Capital Management, L.P. acts as investment manager. RA Capital, its general partner and principals, including Dr. Peter Kolchinsky and Mr. Rajeev Shah, disclaim beneficial ownership beyond their pecuniary interest. The trades were not reported as made under a Rule 10b5-1 plan.

Entities affiliated with RA Capital Management reported open-market purchases of a total of 21,654 shares of Artiva Biotherapeutics common stock on 2026-07-10 and 2026-07-13 at weighted-average prices of $8.9700 and $8.9400 per share. After these trades they report 16,817,573.0000 shares of common stock held indirectly across several managed funds and a separately managed account, while disclaiming beneficial ownership beyond their pecuniary interests.

Artiva Biotherapeutics, Inc. disclosed that investment vehicles managed by RA Capital Management, L.P. made net open-market purchases of 32,876 shares of its common stock. On June 25, 2026, a fund associated with RA Capital bought 31,000 shares at a weighted average price of $8.88 per share, and on June 26, 2026, a related account bought 1,876 shares at a weighted average price of $8.98 per share. Footnotes state these trades occurred in multiple transactions within price ranges of $8.62–$8.98 and $8.97–$9.00. After these transactions, RA Capital–managed entities collectively report indirect holdings in several blocks, including 16,795,919 shares in one fund, reflecting a large existing position with a relatively small incremental purchase.

Artiva Biotherapeutics, Inc. reported open-market purchases of its common stock by investment funds and accounts managed by RA Capital Management, L.P. The transactions covered a total of 531,326 shares at prices around $8.57 to $8.99 per share, with weighted-average prices within disclosed ranges of $8.31 to $9.00. Following these buys, the largest reported indirect position among the reporting entities was 16,763,043 shares of common stock. The Adviser, its general partner and related individuals and funds disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.

Artiva Biotherapeutics, Inc. insider filing shows affiliated RA Capital funds buying additional common stock in open-market transactions. Entities managed by RA Capital purchased a total of 1,027,722 Artiva shares between June 9 and June 11, 2026 at prices around $6.91–$7.91 per share.

After these indirect purchases through RA Capital-managed vehicles, the reporting group is shown holding 16,231,717 shares of Artiva common stock. Footnotes state the adviser and related parties disclaim beneficial ownership except to the extent of their pecuniary interest.

GC Corp. and subsidiary GC Cell Corporation, both 10% owners of Artiva Biotherapeutics, Inc., bought a combined 1,432,291 shares of Artiva common stock in open‑market transactions. The purchases were made on May 11, 2026 at $11.52 per share.

After these transactions, GC Cell Corporation held 1,607,734 Artiva shares indirectly and GC Corp. held 4,391,969 shares directly. Footnotes explain that GC Corp. is a Korean holding company ultimately controlled by its board, whose members may be deemed to share voting and investment power but each disclaims beneficial ownership except for any pecuniary interest.

Artiva Biotherapeutics, Inc. senior vice president of research and development Heather Raymon reported an open-market sale of 3,095 shares of common stock at a weighted average price of $9.0078 per share. According to the company’s sell-to-cover policy, these shares were sold automatically to satisfy tax withholding on vested restricted stock units. After this transaction, Raymon directly holds 148,228 Artiva shares.

Artiva Biotherapeutics, Inc. reported that Chief Tech Operations Officer Christopher Horan sold 7,002 shares of common stock on May 19, 2026 at a weighted average price of $9.0078 per share. The price range for these sales was between $8.7421 and $9.0104.

According to the company’s sell-to-cover policy, these automatic sales were made solely to cover tax withholding obligations arising from the vesting and release of restricted stock units, and were not discretionary trades. After the transaction, Horan directly owned 293,450 shares of Artiva common stock.

Artiva Biotherapeutics COO Jennifer Bush reported an automatic sale of 8,790 common shares to cover tax withholding on vested restricted stock units. The shares were sold in the open market at a weighted average price of $9.0078 per share, within a range of $8.7439 to $9.0104. After this sell-to-cover transaction under the company’s tax policy, she continues to hold 337,920 shares directly.

Artiva Biotherapeutics' Chief Medical Officer, Subhashis Banerjee, sold 7,037 shares of common stock in an open-market transaction at a weighted average price of $9.0076 per share. The company explains these automatic sales were made solely to cover tax withholding obligations tied to vested restricted stock units. Following the sale, Banerjee directly holds 144,963 shares.

Artiva Biotherapeutics, Inc. Chief Executive Officer Fred Aslan reported an open-market sale of 27,116 shares of common stock at a weighted average price of $9.0077 per share. After this transaction, he directly holds 1,535,082 shares.

The company has a “sell-to-cover” policy for tax withholding on vesting restricted stock units, and these shares were sold automatically to cover related tax obligations, not at Aslan’s discretion. Sale prices ranged between $8.7383 and $9.0104.

Artiva Biotherapeutics President & Head of R&D Diego Miralles received new equity awards. He was granted 77,500 shares of common stock as restricted stock units and 232,500 employee stock options with an exercise price of $9.22 per share under the company’s 2025 Inducement Plan.

Following the grants, he directly holds 77,500 shares of common stock and 232,500 options. According to the award terms, 25% of the option shares vest on May 15, 2027, with the remaining shares vesting monthly over the next 36 months.

Artiva Biotherapeutics received a large indirect equity investment from RA Capital–affiliated entities. On May 11, 2026, RA Capital–managed vehicles reported open‑market purchases of 6,510,416 shares of Artiva common stock at $11.52 per share and 2,170,138 Pre-Funded Warrants at $11.5199 per warrant.

Following these trades, the reporting entities indirectly held 15,203,995 shares of common stock and 2,170,138 Pre-Funded Warrants, along with additional indirect common stock positions of 68,320, 826,832, and 264,571 shares through various RA Capital funds and a separately managed account.

The filing states that RA Capital Management, its general partner, and principals disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest. The Pre-Funded Warrants are exercisable immediately, but the Fund cannot exercise them if doing so would push its beneficial ownership above 9.99% of Artiva’s outstanding common stock.

Huston Thad Allen reported acquisition or exercise transactions in this Form 4 filing.

Artiva Biotherapeutics’ Chief Financial Officer, Thad Allen Huston, received an equity award of 220,000 shares of common stock on March 10, 2026. The Form 4 describes this as a restricted stock unit grant under the company’s 2025 Inducement Plan, with no cash purchase price and resulting direct ownership of 220,000 shares.

Sorg Elaine K. reported acquisition or exercise transactions in this Form 4 filing.

Artiva Biotherapeutics director receives stock option grant

Artiva Biotherapeutics, Inc. director Elaine K. Sorg was granted a Director Stock Option covering 27,500 shares on February 18, 2026. The option has a grant price of $0.00 per share, reflecting a compensatory award rather than an open-market purchase.

According to the vesting terms, one-third of the 27,500 shares vested following the grant date. The remaining shares vest monthly over an additional two years following February 18, 2026, aligning the director’s compensation with longer-term company performance.

Artiva Biotherapeutics reported that SVP of Research and Development Heather Raymon received a grant of 46,000 shares of common stock in the form of restricted stock units under the company’s 2024 Equity Incentive Plan. On the same date, 1,521 shares at $4.00 per share were withheld to cover income tax obligations linked to restricted stock unit vesting, leaving Raymon with 151,323 directly owned shares.

Artiva Biotherapeutics, Inc. Chief Tech Operations Officer Christopher Horan reported equity compensation and a related tax withholding transaction in company stock. He received a grant of 117,300 shares of common stock as a restricted stock unit award under the company’s 2024 Equity Incentive Plan. On the same date, 2,187 shares of common stock at a price of $4.00 per share were withheld by the company to cover income tax obligations arising from the vesting of restricted stock unit awards. After these transactions, Horan directly owned 300,452 shares of Artiva’s common stock.

Artiva Biotherapeutics COO and CLO Jennifer Bush reported equity compensation and related tax withholding transactions in company stock. She received a grant of 117,300 shares of common stock as a restricted stock unit award under Artiva’s 2024 Equity Incentive Plan. On the same date, 3,515 shares were withheld by Artiva at a price of $4.00 per share to cover income tax obligations tied to vesting of restricted stock units, rather than sold in the open market. After these transactions, she directly owned 346,710 shares of Artiva common stock.

Artiva Biotherapeutics, Inc. reported that its Chief Medical Officer, Subhashis Banerjee, acquired 102,000 shares of common stock through a grant described as a restricted stock unit award under the company’s 2024 Equity Incentive Plan. Following this equity award, his directly held common stock ownership increased to 152,000 shares.

Artiva Biotherapeutics reported insider equity activity by President and CEO Fred Aslan. He acquired 366,850 shares of common stock through a restricted stock unit award granted under the company’s 2024 Equity Incentive Plan, and 14,600 shares were withheld at $4.00 per share to cover income tax obligations from vesting. Following these transactions, he directly owned 1,562,198 common shares.

Artiva Biotherapeutics, Inc. reported an insider stock sale by its president and CEO, who also serves as a director. On December 15, 2025, the insider sold 3,187 shares of common stock at $6 per share.

Following this transaction, the insider directly owned 1,209,948 shares of Artiva Biotherapeutics common stock. The filing notes that the sale occurred under a Rule 10b5-1 trading plan adopted by the reporting person on July 23, 2024.

Artiva Biotherapeutics, Inc. reported an insider equity transaction for its SVP, Research and Development. On December 12, 2025, the officer received 67,253 restricted stock units (RSUs) of common stock at a price of $0, bringing their directly held common shares to 106,844.

On the same date, the company cancelled several employee stock options held by the officer pursuant to an option exchange, with exercise prices ranging from $5.01 to $13.47, leaving 0 derivative securities beneficially owned. The cancelled options had been scheduled to vest over multi-year periods based on continued service.

Artiva Biotherapeutics granted its Chief Tech Operations Officer 107,156 restricted stock units (RSUs) of common stock on December 12, 2025 under its 2024 Equity Incentive Plan as part of an option exchange.

On the same date, the company cancelled employee stock options covering 77,519 and 9,119 shares at an exercise price of $5.01 and options for 20,519 shares at $13.47, in exchange for the new RSUs. After these transactions, the officer directly beneficially owns 185,339 shares of Artiva common stock.

Artiva Biotherapeutics, Inc. reported that a senior officer (COO, CLO, Secretary and Compliance Officer) exchanged stock options for restricted stock units on December 12, 2025.

The officer received 84,877 restricted stock units granted under the company’s 2024 Equity Incentive Plan at a stated price of $0, bringing direct beneficial ownership to 232,925 shares of common stock.

As part of the same option exchange, the company cancelled employee stock options to buy 41,039, 9,119, 14,202 and 20,519 shares of common stock with exercise prices ranging from $5.01 to $13.47, all of which now show zero derivative securities beneficially owned.

Artiva Biotherapeutics, Inc. President and CEO, who also serves as a director, reported an equity compensation change effective December 12, 2025. The company cancelled several employee stock options listed in the filing, with exercise prices ranging from $5.01 to $13.47 per share, covering multiple grants that were scheduled to vest over multi-year periods.

In exchange for the cancelled options, the reporting person received 869,136 restricted stock units under the company’s 2024 Equity Incentive Plan, recorded at a price of $0 per unit. Following this option-for-RSU exchange, the reporting person beneficially owned 1,213,135 shares of the company’s common stock, held directly.

Artiva Biotherapeutics, Inc. (ARTV) reported an insider equity transaction by its Senior Vice President of Research and Development on a Form 4. On 11/15/2025, 1,375 shares of common stock were surrendered at a price of $3.25 per share, coded as an “F” transaction, which indicates shares withheld to cover taxes related to the vesting of restricted stock units. After this tax withholding event, the reporting person beneficially owned 39,591 shares of Artiva common stock directly. This was a routine administrative transaction tied to equity compensation rather than an open-market sale.

Artiva Biotherapeutics, Inc. (ARTV) reported an insider equity transaction by its Chief Tech Operations Officer. On 11/15/2025, 1,899 shares of common stock were withheld by the company at a price of $3.25 per share to cover income tax obligations tied to the vesting of restricted stock unit awards. After this tax withholding, the officer beneficially owns 78,183 shares of Artiva common stock in direct ownership. This filing is an administrative Form 4 disclosure of equity compensation and related tax settlement rather than an open-market buy or sell.

Artiva Biotherapeutics, Inc. (ARTV) reported an insider equity transaction by its COO, CLO, Secretary and Compliance Officer on a Form 4. On 11/15/2025, the officer had 3,055 shares of common stock withheld at a price of $3.25 per share. These shares were withheld by the company to cover income tax obligations associated with the vesting of restricted stock unit awards, rather than sold in an open-market transaction. After this tax withholding, the officer beneficially owned 148,048 shares of Artiva common stock directly.

Artiva Biotherapeutics, Inc. reported an insider equity transaction by its Chief Financial Officer, Neha Krishnamohan. On 11/15/2025, 3,490 shares of common stock were withheld by the company at a price of $3.25 per share to cover income tax obligations related to the vesting of restricted stock unit awards. After this tax withholding, the reporting person beneficially owns 99,356 shares of Artiva common stock directly.

Artiva Biotherapeutics (ARTV) President and CEO, who is also a director, reported routine equity transactions. On 11/15/2025, 6,347 shares of common stock were withheld by the company at $3.25 per share to cover income taxes from vesting restricted stock units. On 11/17/2025, the insider sold 6,375 shares of common stock at a weighted average price of $3.376 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on July 23, 2024. Following these transactions, the insider directly beneficially owned 343,999 shares of Artiva common stock.

Artiva Biotherapeutics (ARTV) reported an insider transaction on Form 4. The President & CEO and Director sold 25,500 shares of common stock at $6 on 10/17/2025. Following the sale, the reporting person beneficially owned 356,721 shares, held directly.

The filing notes the trade was made under a Rule 10b5-1 trading plan adopted on July 23, 2024.